LMCG Investments 13F: Exits AstraZeneca (AZN) Stake

LMCG Investments sold out of its stake in AstraZeneca PLC (NYSE:AZN), liquidating its entire position of 5,258 shares. The move was disclosed in a Form 13F filing with the Securities and Exchange Commission on October 21, 2026. The fund held 5,258 shares prior to the sale. AstraZeneca shares closed at $168.45 on the day of the filing.

AZN AstraZeneca PLC

$168.45 ▼ -7.06% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in LMCG Investments's AstraZeneca Position

LMCG Investments completely closed its position in the biopharmaceutical company during the period. The firm went from holding 5,258 shares down to zero, representing a total exit from the stock. The shares held a prior value before the complete liquidation.

Other Institutional Activity in AstraZeneca

Other large investors adjusted their holdings in AstraZeneca around the same time. Royal London Asset Management picked up a new position ending with 10,299,563 shares worth about $1.95 billion. Korea Investment also established a new stake, reporting 1,345,26 shares valued at roughly $255.1 million. Amundi grew its holdings by 15,375,659 shares, ending the period with 15,386,149 shares worth about $2.92 billion. Banque Pictet & Cie increased its stake by 163,549 shares, ending with 350,235 shares valued at about $57.1 million. Meanwhile, Montrusco Bolton Investments trimmed its position by 42,009 shares to finish with 176,054 shares worth roughly $28.7 million.

AstraZeneca PLC Stock Up 1.8%

Shares of AstraZeneca recently traded around $171.56 as of October 22, 2026, sitting above the $168.45 close recorded when the filing came out. The stock is up about 1.8% since that report. The share price stands above its 50-day moving average but below its 200-day moving average.

Recent Earnings

AstraZeneca reported trailing-twelve-month revenue of $61.37 billion alongside earnings of $6.69 per share. The next corporate earnings update is scheduled for October 30, 2026.

Dividend

AstraZeneca pays an annual dividend of $3.20 per share, giving the stock a dividend yield of 1.9%.

Analysts Set New Price Targets

Analysts have continued to evaluate the drug maker's market position. On August 24, 2026, CICC initiated coverage on the stock with an outperform rating and a price target of $198.00. Wall Street analysts maintain a consensus buy recommendation on the shares, backed by an average price target of $206.66 across 12 opinions.

About AstraZeneca

AstraZeneca PLC is a Cambridge, United Kingdom-based biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing prescription medicines across major therapeutic areas. Institutional portfolio adjustments reflect ongoing shifts in healthcare sector allocations as large funds rebalance their holdings.

Bottom Line

Investors are keeping a close watch on AstraZeneca ahead of its upcoming earnings report on October 30, 2026. Future regulatory updates and institutional filings will provide more clarity on how major funds view the stock moving forward.